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Abstract
Background: Prostate cancer (PCa) is a major cause of morbidity and mortality in men worldwide. MicroRNAs are
globally downregulated in PCa, especially in poorly differentiated tumors. Nonetheless, the underlying mechanisms
are still elusive. Herein, using combined analysis of microRNAs expression and genomewide DNA methylation, we
aimed to identify epigenetically downregulated microRNAs in PCa.
Results: We found that miR-152-3p was underexpressed in PCa and that lower expression levels were associated
with promoter hypermethylation in accordance with TCGA dataset analysis. Functional in vitro assays suggest that
miR-152-3p suppresses cell viability and invasion potential, whereas it promotes cell cycle arrest at S and G2/M
phases. Additionally, miR-152-3p expression was associated with longer disease-free survival in PCa patients from
TCGA. Finally, TMEM97, which is overexpressed in PCa, was identified as a novel miR-152-3p target gene.
Conclusions: Our findings demonstrate the advantages of using a combinatory approach to identify microRNAs
downregulated due to aberrant promoter methylation. MiR-152-3p downregulation and promoter methylation was
found to be prevalent in primary PCa, which impairs its role in control of cell viability, cell cycle regulation and invasion.
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Background
MicroRNAs (miRNAs) are a class of small (~ 22-nucleotide)
RNAs that mediate post-transcriptional gene silencing by
guiding Argonaute (AGO) proteins to target mRNAs [1, 2],
either by repressing translation or by promoting
destabilization [3]. Target guidance and specificity is mainly
determined by nucleotides at positions 2–7 of the miRNA
(the seed-sequence) [4]. Such mechanisms are critical for
homeostasis maintenance, both under physiological condi-
tions and in cell’s response to environment alterations, in-
cluding stress signals [5]. Thus, a vast number of biological
processes are subject to miRNA-dependent regulation,
encompassing cell proliferation, signaling, differentiation,
stress response, DNA repair, cell adhesion and motility,
inflammation, cell survival, senescence, and apoptosis [1].
Interestingly, miRNA’s expression, processing, and func-
tional output are also stringently controlled [6]. Indeed,
miRNAs’ expression and activity are tightly spatially and
temporally regulated, and its disruption has been extensively
linked to human disease, including the development of
cancer and metastasis formation [1, 7]. Globally, miRNAs
are mostly downregulated in cancer, including that of the
prostate [1]. Multiple mechanism are known to induce
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aberrant transcription factors binding (e.g., p53, MYC),
miRNA biogenesis machinery disruption, RNA editing,
post-transcriptional RNA modifications, Argonaute loading,
and RNA decay [7, 8].
Prostate cancer (PCa) is the most common non-cutaneous
cancer worldwide in men, and a leading cause of cancer-
related death in developed countries [9]. Multiple factors,
comprising age, family history, genetic susceptibility and eth-
nicity, contribute to the high incidence of PCa [10]. Owing to
its complexity and heterogeneity, and despite extensive stud-
ies, the molecular mechanisms that drive prostatic carcino-
genesis are still far from complete understanding. Because
miRNAs regulate a wide range of signaling pathways that are
frequently deregulated in PCa, this class of noncoding RNAs
might be of critical relevance for tumor development and
progression. Thus, its study may provide novel insights into
PCa biology and afford innovative tools for patient manage-
ment, aiding in diagnosis and prognosis assessment, as well
as the identification of new therapeutic targets [11].
Methods
Aim
Here, we attempted to discover new epigenetically regulated
miRNA loci in PCa using a combinatory approach that com-
pared miRNAs expression profiling with DNA methylation
patterns. The candidate microRNAs were subsequently vali-
dated in two large patient cohorts, which included ours and
that of TCGA; in vitro assays were performed to characterize
their role in cancer cell biology, and in silico analysis,
followed by in vitro validation, allowed for the identification
of relevant target mRNAs. Overall, our data extends current
knowledge about epigenetic deregulation and biological sig-
nificance of miRNAs in prostate carcinogenesis. A flow chart
depicting the different steps followed in this study is pro-
vided in Additional file 1: Figure S1. All methods were per-
formed in accordance with the relevant guidelines and
regulations both for tissue samples and in vitro assays.
Patient and samples
PCa tissue samples (n = 100) from patients diagnosed and
primarily treated with radical prostatectomy at Portuguese
Oncology Institute of Porto, Portugal, were prospectively
collected. Fourteen normal prostate tissue (MNPT)
samples, of peripheral zone of prostates without PCa,
from patients submitted to radical cystoprostatectomy
due to bladder cancer, served as controls. All specimens,
promptly frozen at − 80 °C, were cut for nucleic acid ex-
traction. For routine histopathological examination,
formalin-fixed and paraffin-embedded (FFPE) fragments
were also collected. Relevant clinical data was retrieved
from clinical charts. This study was approved by the
institutional ethics committee [Comissão de Ética para a
Saúde- Instituto Português de Oncologia do Porto
Francisco Gentil, EPE (CES-IPOPFG-EPE 215/013)].
Moreover, in compliance with the Helsinki Declaration
and after CES approval, informed consent was obtained
for all patients previously to surgery. Additionally, a Co-
hort of patients available at TCGA were included for val-
idation. The clinical and pathological data of both cohorts
of patients (IPO Porto’s cohort and TCGA’s cohort) in-
cluded in this study is reported in Table 1.
PCa cell lines and demethylation treatment
Prostate cell lines, LNCaP, 22RV1, DU145, PC-3 (malig-
nant), and RWPE (benign) were used for in vitro studies.
LNCaP and 22Rv1 cells were grown in RPMI 1640,
whereas DU145 and PC-3 cells were maintained in MEM
and 50% RPMI-50% F-12 medium, while RWPE was cul-
tured in Keratinocyte-SFM, containing human recombin-
ant Epidermal Growth Factor 1-53 and Bovine Pituitary
Extract (GIBCO, Invitrogen, Carlsbad, CA, USA), respect-
ively. HEK293Ta were maintained in DMEM. All basal
culture media were supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin (GIBCO, Invitro-
gen, Carlsbad, CA, USA). Cells were maintained in an in-
cubator at 37 °C with 5% CO2. All cell lines were G-
banding karyotyped (for validation) and routinely tested
for Mycoplasma spp. contamination (PCR Mycoplasma
Detection Set, Clontech Laboratories).
Table 1 Clinical and pathological data of the patients included
in this study
(A) IPO Porto’s cohort
Clinicopathological features MNPT PCa
Patients, n 14 100
Median age, years (range) 65 (49–80) 65 (49–75)
PSA (ng/mL), median (range) n.a. 8.45 (3.5–23)
pT2 n.a. 60 (60%)
pT3 n.a. 40 (40%)
< 7 n.a. 36 (36%)
= 7 n.a. 58 (58%)
> 7 n.a. 6 (6%)
(B) TCGA’s cohort
Clinicopathological Features NAT PCa
Patients, n 52 497
Median age, years (range) 61 (43–72) 61 (41–78)
pT2 29 (56%) 189 (38%)
pT3 21 (40%) 292 (59%)
pT4 2 (4%) 10 (2%)
< 7 5 (10%) 45 (9%)
= 7 40 (77%) 248 (50%)
> 7 7 (13%) 204 (41%)
MNPT morphologically normal prostate tissue, PCa prostate cancer, NAT
normal adjacent tissue, n.a. not applicable
(A) IPO Porto’s cohort (B) TCGA’s cohort
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One micromolar of the DNA methyltransferases inhibi-
tor 5-aza-2-deoxycytidine (5-Aza-CdR; Sigma-Aldrich,
Schnelldorf, Germany) was used for DNA demethylation.
Cells were harvested and RNA extracted after 72-h expos-
ure to the demethylating agent.
Nuclei acid extraction and bisulfite conversion
DNA was extracted from fresh frozen tissue samples
and cell lines using phenol: chloroform (Sigma). RNA
was isolated using TRIzol (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
Bisulfite conversion of genomic DNA (1000 ng) was
accomplished using EZ DNA Methylation Kit (Zymo Re-
search), following the manufacturer’s instructions.
sgRNA cloning
Complementary single-stranded oligos (Additional file 1:
Table S1) were phosphorylated and annealed by combining
100 μM oligos, 1× T4 PNK Buffer, 1 mM ATP, 5 U T4
PNK and incubating the reaction at 37 °C/30 min, 95 °C/
5 min followed by a ramp down to 25 °C at 5 °C/min.
Annealed oligos were diluted at 1:100 in sterile water and
ligated to plasmid vector lentiCRISPRv2 (gift from Feng
Zhang (Addgene plasmid #52961)) using the following pa-
rameters: 50 ng BsmBI (Fermentas) digested plasmid, 1 μl
diluted oligo duplex, 1× Ligation Buffer (Roche), and
5 U T4 DNA Ligase (Roche) incubated at RT/30 min. The
ligation reactions were used to transform highly competent
Escherichia coli cells according to the manufacturer’s proto-
col [12]. Transformation mixtures were plated in LB-agar
plates. After colony selection, they grew in liquid LB and
plasmid DNA was harvested using PureLink HiPure
Plasmid Maxiprep Kit (Invitrogen, Carlsbad, CA, USA).
The resulting DNA was then subjected to Sanger
sequencing to confirm the correct either the orientation
and sequence of each sgRNA.
Lentivirus production, purification, and transduction
To produce lentivirus, 4 × 106 HEK293T cells per sgRNA
were seeded in ten 100-mm dishes 1 day before transfec-
tion. For each dish, we diluted 10 μg of plasmid DNA
(corresponding to individual sgRNA), 3.5 μg of pVSV-G,
5 μg of pMDL RRE, and 2.5 μg of pRSV-REV in 450 μl of
0.1× TE/H2O, added 50 μl of CaCl2 and incubated 5 min
at RT. Plasmid DNA was precipitated by adding 500 μl 2×
HBS to the solution while vortexing at full speed. The pre-
cipitate was added immediately to the plate and the cells
were incubated for 14 h at 37 °C, after which the medium
was refreshed. Lentivirus-containing supernatants were
collected 60 h post-transfection, filtered through a 0.45-
μm membrane (Milipore Steriflip HV/PVDF) and stored
at − 80 °C. Cell lines were infected with lentivirus superna-
tants supplemented with 8 μg/ml polybrene (Sigma). At
24 h post-infection, medium was replaced and cells were
selected with 2 μg/ml puromycin (Gibco). Antibiotic se-
lection was stopped as soon as no surviving cells remained
in the no-transduction control plate.
PCR and sanger sequencing
Genomic DNA (∼ 1 × 105 cells) from cloned cells was
isolated with DNeasy Blood and Tissue kit (Qiagen). PCR
reactions were carried out with 500 ng of genomic DNA
using Phusion DNA polymerase (Thermo Scientific)
according to the manufacturer’s instructions. The PCR
products were run in a gel and purified using the Agarose
Gel DNA Extraction Kit (Roche). The primer pairs spanning
the target site (covering around 500 bp for each cutting site)
are listed in the Additional file 1: Table S1. Purified PCR
samples (50 ng) were prepared for sequencing using 4 μl of
BigDye terminator v3.1 (Applied Biosystems) and 5 pM
primer in final volume of 20 μl. PCR program: 1 min at 96 °
C (1×), followed by 30 s at 96 °C, 15 s at 50 °C, and 4 min at
60 °C (30×), and finishing with 1 min incubation at 4 °C
(1×). Samples were analyzed in an Applied Biosystems
3730xl DNA Analyser. The quantitative assessment of
CRISPR-Cas9 genome editing was done using a freely avail-
able online software—TIDE [13]. Specifically, using Sanger
sequencing reactions (sgRNA NT, sgTMEM97#1.1,
sgTMEM97#1.2, sgTMEM97#2.1 and sgTMEM97#2.2), in-
sertions/deletions (indels) and editing efficacy was assessed
by TIDE software [13]. For that, the chromatogram sequence
files of respectively the control sample (i.e., transduced with
the sgRNA NT) and the test sample (i.e., transduced with
the target sgRNA) were analyzed. As output, the quantitative
spectrum of indels around the cut site was obtained [13].
MicroRNA expression profiling
MiRNAs expression was assessed in ten PCa and four
MNPT using microRNA Ready-to-Use PCR Human
Panel (I + II) v2.R (Exiqon, Vedbaek, Denmark), com-
prising 752 miRNAs as previously described [14, 15]. Ex-
tracted RNAs were submitted to cDNA synthesis using
miRCURY LNA Universal RT microRNA PCR (Exiqon,
Vedbaek, Denmark) following the manufacturer’s in-
structions. Data were analyzed using the comparative Ct
method, and the median value was calculated for refer-
ence genes’ expression normalization. MiRNAs with fold
change of − 1.5 in PCa compared with MNPT were con-
sidered downregulated.
MicroRNA’s promoter methylation analysis in prostate
tissues
All DNA samples were assessed for integrity, quantity, and
purity by electrophoresis in a 1.3% agarose gel, picogreen
quantification, and nanodrop measurements. All samples
were randomly distributed into 96-well plates. Bisulfite con-
version of 500 ng of genomic DNA was performed using
the EZ DNA Methylation Kit (Zymo Research) following
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the manufacturer’s instructions. Two hundred nanograms
of bisulfite-converted DNA was used for hybridization on
the HumanMethylation450 BeadChip (Illumina). Briefly,
samples were whole-genome amplified followed by enzym-
atic end-point fragmentation, precipitation, and resuspen-
sion. The resuspended samples were hybridized onto the
BeadChip for 16 h at 48 °C, then washed. A single nucleo-
tide extension with labeled dideoxynucleotides was per-
formed, and repeated rounds of staining were applied with
a combination of labeled antibodies differentiating between
biotin and DNP.
HumanMethylation450 BeadChip data were processed
using Bioconductor minfi package [16]. The “lllumina”
procedure that mimics the method of GenomeStudio
(Illumina) was performed, including background correc-
tion and normalization considering the first array of the
plate as reference. Probes with one or more single nucleo-
tide polymorphisms (SNPs) with a minor allele frequency
(MAF) > 1% (1000 Genomes) in the first 10 bp of the in-
terrogated CpG were removed. The methylation level (β
value) for each of the 485,577 CpG sites was calculated as
the ratio between the methylated probe intensity and the
overall intensity (sum of methylated and unmethylated
probe intensities) multiplied by 100. After normalization
step, probes mapped within X and Y chromosomes were
removed. All analyses were performed in human genome
version 19 (hg19), and data was deposited in GEO reposi-
tory under accession number GSE52955.
TCGA dataset analysis
Data on miRNA expression and clinical information
(when available) from PCa and matched normal tissue
samples was retrieved from The Cancer Genome Atlas
(TCGA) database. The mRNA expression data from sam-
ples hybridized at University of North Carolina, Lineber-
ger Comprehensive Cancer Center, using Illumina HiSeq
2000 mRNA Sequencing version 2, were downloaded
from data matrix including 494 miRNA-Seq, 496 RNA-
Seq, and 498 Methylation Array for PCa samples and 52
matched normal adjacent tissue samples (NAT). To pre-
vent duplicates, when there was more than one portion
per patient, median values were used. The provided value
was pre-processed and normalized according to “level 3”
specifications of TCGA. Clinical data of each patient was
provided by Biospecimen Core Resources (BCRs). Data is
available for download through https://gdc-portal.nci.nih.
gov/projects/TCGA-PRAD.
Real-time quantitative PCR (RT-qPCR)
MiR-152-3p transcript levels were assessed using Taq-
Man MicroRNA Assay (assay ID: 000475; Applied Bio-
systems) and normalized with RNU48 (assay ID: 001006;
Applied Biosystems).
Real-time quantitative PCR analysis was performed
using gene-specific primers and normalized using GUSB
housekeeping gene (Additional file 1: Table S1). Specific-
miRNA cDNA was obtained using TaqMan MicroRNA
Reverse Transcription Kit from Applied Biosystems (Fos-
ter City, CA, USA). Total cDNA synthesis was per-
formed using high-capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA).
NOL4 and TMEM97 mRNA levels were confirmed in
the same group of tissue samples previously indicated. A
total of 300 ng was reverse transcribed and amplified
using TransPlex® Whole Transcriptome Amplification
Kit (Sigma-Aldrich®, Schnelldorf, Germany) with subse-
quent purification using QIAquick® PCR Purification Kit
(QIAGEN, Hilden, Germany), according to the manufac-
turer’s instructions. Expression levels were evaluated
using TaqMan® Gene Expression Assays (Applied Biosys-
tems, Foster City, CA, USA), and GUSB was used as a
reference gene for normalization.
The expression of each gene or small RNA was ob-
tained using the formula: Relative expression = (Target
gene mean quantity/Reference gene mean quantity). Ra-
tios were then multiplied by 1000 for easier tabulation.
Each plate included multiple non-template controls, and
serial dilutions (× 10) of a cDNA obtained from human
prostate RNA (Carlsbad, CA, USA) were used to con-
struct a standard curve for each plate. All experiments
were run in triplicates (Additional file 1: Table S1).
DNA methylation analysis
DNA methylation analysis was performed by quantita-
tive methylation PCR (qMSP) using KAPA SYBR FAST
qPCR Kit (Kapa Biosystems, MA, USA) and pyrose-
quencing. All reactions were run in triplicates in 384-
well plates using Roche LightCycler 480 II, with β-actin
(ACTB) as internal reference gene for normalization. Pri-
mer sequences (Additional file 1: Table S1) were de-
signed using Methyl Primer Express 1.0 and purchased
from Sigma-Aldrich (St. louis, MO, USA).
For pyrosequencing, specific sets of primers for PCR
amplification and sequencing were designed using a specific
software pack (PyroMark assay design version 2.0.01.15).
Primer sequences were designed, when possible, to
hybridize with CpG-free sites to ensure methylation-
independent amplification. PCR was performed under
standard conditions with biotinylated primers, and the
PyroMark Vacuum Prep Tool (Biotage, Uppsala, Sweden)
was used to prepare single-stranded PCR products, accord-
ing to the manufacturer’s instructions. Pyrosequencing
reactions and methylation quantification were performed in
a PyroMark Q96 System version 2.0.6 (Qiagen, Hilden,
Germany) using appropriate reagents and recommended
protocols (Additional file 1: Table S1).
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Pre-miR transfections
To overexpress miR-152-3p, synthetic, commercially
available, miRNAs’ precursors (pre-miR-152-3p, ID:
PM12269; pre-miR-NC, ID: AM17110; Ambion, Carls-
bad, CA, USA) were transfected at 30 nM. Transfections
were performed using Oligofectamine (Invitrogen, Carls-
bad, CA, USA), per manufacturer’s instructions.
Viability assay
Cell viability was evaluated by MTTassay. Briefly, PCa cells
were seeded onto 96-well flat-bottomed culture plates,
allowed to adhere overnight later (number of cells plated
before transfection: LNCaP: 10000 cells/well; PC3: 3000
cells/well), and transfected 24 h later. At each time point, 0.
5 mg/ml of MTT reagent [3-(4, 5dimethylthiazol-2-yl)-2, 5-
diphenyl-tetrazolium bromide] was added to each well, and
the plates were incubated in the dark for 1 h at 37 °C. For-
mazan crystals were then dissolved in DMSO and absorb-
ance was read at 540 nm in a microplate reader (FLUOstar
Omega, BMG Labtech, Offenburg, Germany), subtracting
the background, at 630 nm. The number of cells was calcu-
lated using the formula: [(OD experiment x Number of
cells at day 0)/Mean OD at day 0]. Three replicates were
performed for each condition and at least three independ-
ent experiments were carried out.
GFP-competitive proliferation assay
LNCaP cells were infected with sgRNAs targeting the
exon 1 or exon 2 of TMEM97. Separately, we generated
polyclonal LNCaP cells stably expressing GFP using
pLX304-GFP30 (gift from David Root; Addgene plasmid #
25890). GFP expressing cells were mixed in a 1:3 ratio
with cells containing individual sgRNAs. The percentage
of GFP-expressing cells was assessed by flow cytometry at
the beginning of the experiment (T = 0) and every 72 h
onwards (T = 3d; T = 6d, and T = 9d). For each condition,
10,000 events were recorded. The cells were measured on
a BD FACSCalibur cytometer (BD Biosciences, San Jose,
CA, USA) and analyzed using FlowJo software.
Apoptosis evaluation
Evaluation of apoptosis was performed using APOPercen-
tage apoptosis assay kit (Biocolor Ltd., Belfast, Northern
Ireland) according to the manufacturer’s instructions. PCa
cells were seeded onto 24-well plates (LNCaP: 50000
cells/well, and PC3: 30000 cells/well) and 24 h later were
transfected. Apoptotic cells were assessed at the end of
the day 3, in a FLUOstar Omega microplate reader at
550 nm and the background subtracted at 620 nm. The
results were normalized to number of viable cell obtained
in the MTT assay according to the following formula (OD
of apoptosis assay at 72 h/ OD of MTTat 72 h).
Cell cycle analysis
Cell cycle distribution of LNCaP and PC3 cells was deter-
mined by flow cytometry. Briefly, 72 h after transfections,
5 × 105 harvested cells were fixed overnight at 4 °C with
70% cold ethanol. After cold PBS washing, cells were re-
suspended in staining Propidium Iodide Solution (Cytognos
S.L, Salamanca, Spain) and incubated for 30 min at room
temperature. All cells were then measured on a Cytomics
FC500 flow cytometer (Beckman Coulter, Fullerton, CA,
USA) and analyzed using Modfit LT (Verity Software
House, Inc., Topshan, Maine, USA).
Cell invasion assay
Cell invasion was determined using BD BioCoat Matrigel
Invasion Chamber (BD Biosciences, Franklin Lakes, NJ,
USA). Briefly, 5 × 104 cells/mL of LNCaP or PC3 cells
were added to the upper chamber. Both cell lines were
transfected for 72 h with miRNA molecules, after which,
the non-invading cells were removed with cotton swabs
from the upper side of the membrane. The membrane
bottom containing invading cells was fixed in methanol,
washed in PBS, and stained with DAPI (Vector Laborator-
ies, Burlingame, CA). All the invading cells were counted
under a fluorescent microscope. PC3 cell line invasion
capability was quantified upon trans-well matrigel inva-
sion assays (n = 3 for each sample) comparing pre-miR-
152-3p to pre-miR-NC cells. Error bars in all panels indi-
cate standard deviation, unless otherwise specified.
Transcriptomic evaluation of altered genes following miR-
152-3p manipulation
Cells (LNCaP: 400000 cells/well, and PC3: 150000 cells/
well) were plated in 6-well, in the day before transfection.
Cells were collected 72 h post transfection and RNA was
extracted and used as template for cDNA synthesis. RT-
qPCR was performed as previously described and data an-
alyzed according to the comparative Ct method [17].
Gene expression microarrays
RNA was extracted from tissue samples using TRIzol
(Invitrogen by Life Technologies, Carlsbad, CA), as previ-
ously described [18], and 1 μg of RNA was processed into
cDNA and hybridized to Affymetrix GeneChip Human
Exon 1.0 ST arrays, following the manufacturer’s recom-
mendations [19]. The Affymetrix Expression Console v1.1
software was used to obtain exon-level robust multi-array
average (RMA)-normalized expression values for the core
probe sets only. The data is freely available in GEO reposi-
tory under accession number GSE42954.
Luciferase assay
A reporter plasmid containing a binding site at NOL4 or
TMEM97 3′UTR for miR-152-3p (GeneCopoeia, Rock-
ville, MD, USA) was co-transfected into HEK293Ta cells
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using Lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA, USA). Thirty nanomolars of synthetic pre-
miRNA was used. Luciferase activity was assessed with
the Secrete-Pair™ Dual Luminescence Assay Kit (GeneCo-
poeia, Rockville, MD, USA) according to the manufac-
turer’s instructions. The ratio of luminescence intensities
(RLU, Relative Light Unit) of the GLuc (Gaussia luciferase)
over SEAP (secreted Alkaline Phosphatase) was obtained
as follows: GLuc/SEAP, for each triplicate.
Statistical analysis
Non-parametric tests (Kruskal-Wallis and Mann-Whitney
U test) were used for group comparisons analysis for both
expression and methylation levels for the two patient co-
horts (IPO’s and TCGA) and for the in vitro assays. Corre-
lations between expression levels and methylation were
evaluated by Spearman’s correlation test. Data are shown
as mean ± s.d., unless otherwise specified. Student’s t test
was used for invasion assays. To evaluate the prognostic
value of mir152 and TMEM97 expression in PCa patients
from the TCGA dataset, univariable (Log-rank test) and
multivariable (Cox regression) analyses of disease-free sur-
vival were performed, where putative confounding effects
(Gleason score and patients’ age) were considered.
Disease-free survival was calculated from the date of the
radical prostatectomy to the date of relapse, or date of last
follow-up or death if relapse-free. For the purposes of sur-
vival analyses, high gene expression was considered for
samples within the 90th percentile (10% of samples with
highest gene expression values). All statistical tests were
two-sided. All experiments were run in triplicate.
Statistical analysis was carried out using Graph Pad Prism
version 5 and IBM SPSS statistics version 22. Significance
level was set at p < 0.05.
Results
Identification of hypermethylated and downregulated
microRNAs in prostate cancer
Global miRNA expression was assessed using microRNA
Ready-to-Use PCR Human Panel (I + II) v2.0 (Exiqon,
Vedbaek, Denmark). To identify differentially expressed
miRNAs in PCa, compared to morphologically normal
prostate tissue (MNPT), 740 miRNAs were profiled in
10 PCa tissues and 4 MNPT [20]. Using a cutoff value of
log fold change < − 1.5, 39 miRs were found downregu-
lated in PCa compared to MNPT (Additional file 1:
Table S2 and Figure S1). From these miRNAs, 10 were
selected for validation in a larger and independent data-
set (miR-10a, miR-23b, miR-27b, miR-135b, miR-143,
miR-152-3p, miR-187, miR-204, miR-205, miR-221), i.e.,
the miRNAseq expression data from PCa patients and
matched normal samples deposited in The Cancer
Genome Atlas (TCGA) (n = 326 and n = 52, respectively)
(Fig. 1a–c and Additional file 1: Figure S2).
We also determined global differences in DNA methyla-
tion in the prostate tissues [21]. This cohort was com-
posed of 5 MNPT and 25 PCa. DNA samples were
hybridized on the Infinium DNA methylation BeadChip
platform (Illumina), which analyzes more than 450,000
CpG sites in the genome [22]. After normalization, we fil-
tered out poor-quality probes and those containing single
nucleotide polymorphisms (SNPs; > 1%) [23] and copy
number variations (CNV; > 5%) in the detection sequence.
Following these filters, DNA methylation profiling dis-
closed 38 hypermethylated promoter regions in known
miRNA regions, three of which were further validated in
TCGA dataset (Additional file 1: Table S2 and Figure S3).
Because gene expression and DNA promoter methylation
correlate with gene regulatory activity status, we merged
the results of the two analytical platforms (expression by
Exiqon platform and methylation profiling by Illumina) to
identify miRNAs with decreased expression associated with
promoter hypermethylation in PCa. From this combined
analysis, 5 miRNAs emerged as simultaneously downregu-
lated and hypermethylated in PCa: miR-10a, miR-23b, miR-
27b, miR-34c, and miR-152-3p (Fig. 1a; Additional file 1:
Table S2, highlighted in blue). In TCGA dataset, the com-
mon microRNAs were confirmed to be downregulated in
primary PCa compared to noncancerous prostate tissues
(Fig. 1b), but miR-34c showed no statistical significance.
Moreover, and except for miR-10a, all displayed signifi-
cantly lower expression in PCa in comparison with
matched non-cancerous prostate tissues (Fig. 1c). Because
miRNA’s promoter methylation status was available at
TCGA database, these data were also retrieved and it con-
firmed our finding of increased methylation indexes in
these miR’s obtained with the Infinium 450 K DNA methy-
lation profiling platform (Fig. 1d). Then, we focused our
study on miR-152-3p as it fulfilled the criteria for downreg-
ulation associated with promoter hypermethylation in PCa.
Remarkably, we had already suggested that miR-152-3p
was regulated by DNA methylation in PCa [21, 24], con-
firming previous published findings [25, 26] which support
the observations that miR-152-3p is a common epigeneti-
cally regulated miRNA in PCa.
MiR-152-3p expression and promoter methylation
analysis in prostate cells
MiR-152-3p is located at chromosome 17q21.32, within an
intronic region of COPZ2. Data from the 450 K array re-
vealed that 9 probes targeting this locus were differentially
methylated (Fig. 2a). The cg05850656 and cg24389730
showed the highest β values (0.55 and 0.53). These probes
map to TSS200-Body for miR-152-3p-COPZ2 locus. To
further validate these findings, miR-152-3p (Fig. 2b) and
COPZ2 (Fig. 2c) expression levels were assessed in our co-
hort of prostatic tissues (PCa = 100 and MNPT= 14) and
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downregulation of both in PCa compared to MNPT was
confirmed (p < 0.0001 and p = 0.0022, respectively).
In both patients’ cohorts, miR-152-3p and COPZ2 ex-
pression levels were inversely and significantly correlated
with methylation levels in PCa samples (p = − 0.444, p < 0.
0001, and p = − 0.435, p < 0.0001 for IPO Porto cohort;
p = − 0.331, p < 0.0001 and p = − 0.561, p < 0.0001, TCGA
Cohort, respectively).
Pyrosequencing analysis demonstrated that the pro-
moter shared by miR-152-3p and COPZ2 was aberrantly
methylated in PCa (Fig. 2d; p < 0.0001).
In LNCaP, DU 145, and PC3 cells, miR-152-3p and
COPZ2 expression levels were also significantly lower than
those found on RWPE cells, which are benign epithelial
prostate cells (Figs. 2e, f), whereas promoter methylation
levels followed the opposite trend, specifically for the latter
two cell lines—LNCaP and PC3 (Fig. 2g). These findings
suggest that miR-152-3p is transcribed in parallel with its
host gene, COPZ2. Exposure of PCa cells to demethylating
agent 5-Aza-2-deoxycytidine (5-Aza-CdR) caused a 38 and
67% reduction in COPZ2-miR-152-3p promoter methyla-
tion levels, in LNCaP (p = 0.0411) and PC3 cells (p = 0.
0043), respectively (Fig. 2h). Nonetheless, the impact in
gene expression differed as miR-152-3p re-expression was
observed in both cell lines (LNCaP, FC: 1.75; and PC3, FC:
1.94) (Fig. 2i), whereas COPZ2 transcript levels were only
significantly restored in PC3 cells (FC: 3.98) (Fig. 2j).
MiR-152-3p attenuates malignant phenotype in vitro
Using in vitro assays, we found that miR-152-3p overexpres-
sion significantly decreased cell viability in both LNCaP and
PC3 cells (Fig. 3a, d) and promoted a significant accumula-
tion of cells in S and G2/M phases (Fig. 3b, e). Accordingly,
at transcriptional level, both cell lines displayed a significant
Fig. 1 Identification of miRNAs downregulated by DNA methylation in prostate cancer, using a combinatorial approach. a Venn diagram of the
intersection of the miR expression (Exiqon) versus DNA methylation (Infinium HumanMethylation450 BeadChip) for miRNA promoters. Intersection is
shown for the downregulated miRNAs and hypermethylated miRNAs. The five common miRNAs based on expression level and DNA methylation in
PCa tissues are miR-10a, miR-23b, miR-27b, miR-34c, and miR-152-3p. b Independent validation using the TCGA Prostate RNA-seq cohort for miR-10a,
miR-23b, miR-27b, and miR-152-3p in PCa samples compared to NAT samples. c MiRNA expression analysis of 52 matched normal and PCa samples
pairs using TCGA cohort. Except for miR-10a, all miRs were significantly downregulated in PCa. d DNA methylation levels (β-Values) for each probe in
specific miRNA loci, comparing normal and PCa samples using TCGA Prostate 450 K cohort. Overall, DNA methylation gain (hypermethylation) was
found in PCa samples. NAT: Normal Adjacent Tissue; PCa: Prostate Cancer; Mann-Whitney U test: *p < 0.05, **p < 0.01, ***p < 0.001
Ramalho-Carvalho et al. Clinical Epigenetics  (2018) 10:40 Page 7 of 15
decrease of several cell cycle regulators (Fig. 3c, f). Con-
versely, miR-152-3p’s mimic transfection associated with in-
creased apoptosis in LNCaP (p = 0.0286) and PC3 (p = 0.
0286) cells (Fig. 3g; Additional file 1: Figure S4). These re-
sults were further supported by the significantly reduced NF-
kB expression in both PCa cell lines, as well as significantly
increased CASP3 expression levels, although only in PC3
transfected cells (Fig. 3h, i). Moreover, miR-152-3p overex-
pression significantly reduced PC3 invasion ability in PC3
cells (p = 0.0286; Fig. 3j) and associated with specific epithe-
lial–mesenchymal transition genes’ downregulation. Indeed,
along with TWIST and VIM downregulation, MAPK1,
SMAD4, and STAT3 were significantly downregulated after
miR-152-3p restored expression in both LNCaP and PC3
cells (Fig. 3k, l).
miR-152-3p targets NOL4 and TMEM97
Because the previous results suggested that miR-152-3p
was an onco-suppressor, we sought to identify its targets
for post-transcriptional regulation, using a combination
of multiple in silico target prediction tools (putative tar-
gets must contain at least one miRNA response element
(MRE)) (Additional file 1: Table S3) and a publicly avail-
able gene expression dataset. Among the 329 genes
Fig. 2 COPZ2-miR-152-3p transcriptional unit’s DNA methylation and expression validation in IPO Porto’s cohort of prostate samples. a
HumanMethylation450 BeadChip data for miR-152-3p locus, showing a significant increase in cg21384971, cg05096161, cg05850656, cg06598332,
cg10382221, and cg24389730. b Significant miR-152-3p downregulation in PCa (n = 100) compared to morphologically normal prostate tissues
(MNPT, n = 14), as determined by RT-qPCR (p < 0.0001). c Significantly decreased COPZ2 transcript levels in PCa samples (p = 0.0022). d COPZ2-
miR-152-3p promoter hypermethylation in PCa samples determined by pyrosequencing (p = < 0.0001). e MiR-152-3p expression levels in PCa cell
lines compared to benign RWPE cells [expression (E):1] assessed by RT-qPCR. Expression is significantly lower in LNCaP (E ~ 0.13), DU145 (E ~ 0.54)
and PC3 (E ~ 0.09) cells. f Significantly lower COPZ2 expression levels by RT-qPCR in LNCaP (E ~ 0.005), DU145 (E ~ 0.17) and PC3 (E ~ 0.12) cells
compared to RWPE (E 1). g Prostate cell lines’ DNA methylation profiling. LNCaP (FC of methylation levels: ~ 59) and PC3 (FC: ~ 7) cells showed
increased miR152-COPZ2 promoter hypermethylation compared to RWPE (FC: 1), 22RV1 and DU145 cells. h A 72-h 5-Aza-CdR exposure, associated
with significant decrease in promoter methylation levels of the transcriptional unit COPZ2-miR-152-3p in LNCaP (decreased ~ 40%) and PC3
(decreased ~ 68%) cells. LNCaP and PC3 cells miR-152-3p (i) and COPZ2’s (j) expression levels following 72-h exposure to 5-Aza-CdR associated
with increased miR-152-3p expression levels (FC:1.75; 1.95, respectively) and COPZ2 (FC:1.12; 3.98, respectively). Error bars represent the s.d. for
three biological replicates. Mann-Whitney U test: *p < 0.05, **p < 0.01, ***p < 0.001. β values range from 0 to 1 and were determined by the ratio
of the methylated probe intensity and the overall intensity (sum of methylated and unmethylated probe intensities). MNPT: Morphologically
Normal Prostate Tissue; PCa: Prostate Cancer; 5-Aza-CdR: 5-aza-2-deoxycytidine
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predicted as miR-152-3p targets in silico, only six—
BEND4, ELOVL2, NOL4, OAS2, SLC7A11, and
TMEM97—disclosed a gene expression log fold change
> 1.5 in PCa samples (n = 368) analyzed by GeneChip
Human Exon ST Array (Fig. 4a). Moreover, forced ex-
pression of miR-152-3p caused a significant downregula-
tion of BEND4, ELOVL2, and TMEM97 in LNCaP cells
(Fig. 4b), whereas in PC3 cells, only NOL4 transcript
levels significantly diminished following miR-152-3p’s
overexpression (Fig. 4c). LNCaP cells overexpressing
miR-152-3p exposed to 5-Aza-CdR showed significantly
reduced TMEM97 expression levels (Fig. 4d), and NOL4
was downregulated in PC3 cells (Fig. 4e).
To further confirm the biological significance of our
previous findings, NOL4 and TMEM97 expression levels
were assessed in two independent cohorts of PCa patients
(from our institution and from TCGA). Remarkably, we
found that TMEM97 and NOL4 expression levels were
Fig. 3 miR-152-3p overexpression associated with attenuated malignant features in LNCaP and PC3 cells. a, dmiR-152-3p overexpression in LNCaP and PC3
cells significantly decreased cell viability compared to pre-miR-NC transfected cells (MTT assay at 24, 48, and 72 h). b, e Cell cycle arrest at S and G2/M phases
was depicted for LNCaP and PC3 cells overexpressing miR-152-3p (cytometry analysis was performed 72 h after transfection). c, f Reduced transcription levels of
several cell cycle-promoting genes in miR-152-3p overexpressing LNCaP and PC3 cells. g MiR-152-3p overexpression associated with significant increase in
apoptosis compared to cells transfected with negative control miRNA. h, i Apoptosis-related genes’ expression levels were deregulated in PCa miR-152-3p
overexpressing cells. Significantly reduced NF-kB levels were found in both miR-152-3p overexpressing cell lines. j MiR-152-3p forced expression in LNCaP and
PC3 cells associated with a significant decrease number of cells invading through the Matrigel coated Boyden chamber assay. k, l Transcriptional deregulation
of EMT and invasion-related genes in miR-152-3p transfected LNCaP and PC3. Differential MET, mTOR and MMP9S results suggest cell-specific gene regulation.
TGFB3 overexpression and EMT markers STAT3, TWIST, or VIM decrease was shared by both miR-152-3p overexpressing cells. Error bars represent the s.d. for three
biological replicates. Mann-Whitney U-test: *p <0.05, **p <0.01, ***p < 0.001
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significantly upregulated in PCa cases from both cohorts,
compared to normal prostate tissues (p = 0.0132 and p =
0.0004, respectively, in IPO Porto’s cohort; p < 0.0001 and
p < 0.0001, respectively, in TCGA cohort; Fig. 4f, g).
TMEM97 knockdown decreases cell proliferation
Since both NOL4 and TMEM97 3′UTRs contain a MRE
for miR-152-3p (Fig. 5a, left panel), the functional inter-
action between miR-152-3p and NOL4, on the one hand,
and miR-152-3p and TMEM97, on the other hand, was
investigated using luciferase assays. Interestingly, a 30%
reduction (p = 0.0022) in luciferase activity for the
TMEM97 MRE was found, although only a 10% decrease
was depicted for the NOL4 MRE (Fig. 5a, right panel).
Thus, we tested 4 individual sgRNAs designed to target
TMEM97.We validated the candidate sgRNAs with a com-
petitive proliferation assay. LNCaP cells were transduced
with the indicated sgRNAs and allowed to proliferate for
9 days. No clonal selection was performed; thus, cells’
population not only comprises a pool of homozygous/het-
erozygous mutants, but also unmutated cells (Additional
file 1: Figure S5).
CRISPR-Cas9-mediated knockout of TMEM97 with four
different sgRNAs (sgTMEM97 exon#1 and exon#2) in
Fig. 4 Identification of putative targets of miR-152-3p in PCa cell lines. a Genes selected for validation in our experimental settings: combining in
silico prediction targets with genome-wide expression using GeneChip® Human Exon ST Array. b MiR-152-3p overexpression in LNCaP cells associ-
ated with significant decreased levels of BEND4 (~ 40%), ELOVL2 (52%) and TMEM97 (40%) as determined by RT-qPCR. c PC3 miR-152-3p’s trans-
fected cells displayed significantly decreased NOL4 expression (approximately 50%). d, e Effect of 5-Aza-CdR treatment in the selected target
genes transcript levels in LNCaP revealed TMEM97 downregulation (up to 35%), whereas in PC3 cells it associated with significantly decreased
NOL4 transcript levels (− 30%). NOL4 and TMEM97 upregulation in PCa tissues. f Significantly higher NOL4 and TMEM97 expression in PCa tissue
samples (n = 100) compared with morphologically normal prostate tissue (n = 14), determined by RT-qPCR. g Expression levels in TCGA Prostate
by RNA-seq cohort (NAT: n = 52; PCa: n = 497). MNPT: Morphologically Normal Prostate Tissue; NAT: Normal Adjacent Tissue; PCa: Prostate Cancer.
Error bars represent the s.d. for three biological replicates. Mann-Whitney U-test: *p < 0.05, **p < 0.01, ***p < 0.001
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LNCaP cells resulted in a significant decrease in proliferation
(Fig. 5b). Remarkably, all four sgRNAs significantly dimin-
ished TMEM97 mRNA levels (Fig. 5c), probably due to
nonsense-mediated decay [27]. Cas9-nuclease activity gener-
ates DNA double-strand breaks that result in deletions and
insertions at the vicinity of the sgRNA recognition site. We
examined the range of deletions/insertions caused by each
sgRNA targeting TMEM97 (Additional file 1: Figure S5). All
the sgTMEM97 caused on-target indels, with a percentage
ranging from 42.3–79.2%.
Overall, the sgRNAs targeting TMEM97 mimicked the
restoration of miR-152, suggesting that this gene is re-
quired for LNCaP cells growth.
miR-152, TMEM97, and NOL4 clinical potential in PCa
Lastly, to further evaluate the biological significance of the
previous findings in primary PCa, the prognostic value of
miR-152, NOL4, and TMEM97 expression levels was
assessed in both PCa patients’ cohorts. Although, no associ-
ations were found in IPO Porto’s cohort, in TCGA’s cohort,
higher miR-152-3p expression levels (90th percentile) pre-
dicted longer disease-free survival in univariable analysis
(Log-rank test p = 0.004; Fig. 6a) and in multivariable Cox
regression analysis adjusted for patients’ age and Gleason
score (HR = 0.228, p = 0.012; Table 2). However, TMEM97
or NOL4 expression levels did not significantly associate
with PCa patients’ outcome (Fig. 6b, c, Table 2).
Discussion
MiRNAs are key players in cellular differentiation and
homeostasis, being involved in regulation of transcrip-
tional programs through the elimination of aberrant
transcripts and suppression of random fluctuations in
transcript copy number [28]. Thus, its deregulation
impairs cellular homeostasis and is involved in the emer-
gence of several pathologies, including PCa.
In this study, we aimed to extend current knowledge on
the impact of epigenetic deregulation of miRNAs expres-
sion in PCa. For that purpose, we used a combined analysis
that allowed the identification of downregulated and aber-
rantly methylated microRNAs. Interestingly, only 8% of
downregulated miRNAs in PCa tissues were found to be
simultaneously aberrantly methylated. Thus, promoter
hypermethylation does not seem to be a prevalent mechan-
ism underlying microRNA downregulation in this cancer
model, and other causes, whether genetic [29], epigenetic
[30] or microenvironment-related (e.g., abnormal AR sig-
naling [31]), are likely to be more frequent. Notwithstand-
ing, we have recently shown that aberrant microRNA
promoter methylation might constitute a clinically useful
tool for PCa detection and prognostication [24]. Although
the number of candidate microRNAs was small, the com-
bined approach used in this study seems to be more robust
and efficient than each strategy (i.e., micro-RNA expression
analysis and differential methylation mapping) alone,
Fig. 5 NOL4 and TMEM97 are miR-152-3p targets a Schematic representation of the miR-152-3p’s MRE in NOL4 and TMEM97. Luciferase activity in HEK293Ta
cells co-transfected with reporter constructs containing NOL4 MRE or TMEM97 MRE and either pre-miR-152-3p or pre-miR-NC. b Validation of candidate sgRNAs
for TMEM97 by a competitive proliferation assay in LNCaP cells. c SgRNA NT indicates a nontargeting. GFP levels were measured by flow cytometry. Values are
normalized to day 0 (T =0). 3′UTR: 3′ Untranslated Region; MRE: miRNA response element Mann-Whitney U test: *p <0.05, **p < 0.01, ***p <0.001
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considering the significantly higher proportion of validated
candidates obtained compared to previous studies from our
group [15, 21]. Moreover, the results also validate this ap-
proach as it confirmed previous reports on miR-23b and
miR-27b (members of the cluster miR-23b/27b/24-1)
downregulation associated with promoter methylation in
PCa [32–34]. Remarkably, two novel microRNAs within
this category were found—miR-10a and miR-152-3p—al-
though only the latter was validated in two independent
datasets.
Interestingly, several miRNAs, including miR-135b, miR-
143, miR-187, miR-204, miR-205 and miR-221 that were
commonly downregulated in the Exiqon expression dataset,
were also downregulated in TCGA dataset. In contrast, the
number of putatively downregulated microRNAs due to ab-
errant DNA methylation found in the HumanMethyla-
tion450 BeadChip and validated in TCGA dataset was
much smaller. Thus, our data indicate that miRNA expres-
sion’s profiling is more likely to identify bona fide miRNA
deregulated due to promoter methylation compared to
DNA methylation profiling, as aberrant DNA methylation
might not indicate effective transcriptional silencing. Never-
theless, DNA methylation profiling might be particularly
suitable for integrative analytic approaches [35].
Because miR-152-3p fulfilled the criteria for methylation-
associated downregulation and it had not been previously
reported in PCa, we sought to investigate its role in prostate
carcinogenesis. Our study indicates that miR-152-3p is a
sense-oriented intronic miRNA that forms a transcriptional
unit (TU) with the respective host gene, COPZ2, being
processed as part of the host gene mRNA [36, 37]. Globally,
aberrant promoter methylation associated with simultan-
eous downregulation of COPZ2-miR152 expression. This
further supports that host gene promoter methylation sta-
tus is, indeed, associated with miRNAs deregulation, as
previously suggested [26]. Nonetheless, the results of 5-
Aza-CdR exposure in LNCaP suggest that this is not the
only mechanism regulating COPZ2-miR152 expression,
and we are tempted to speculate whether an independent
promoter might be located upstream in the host gene, as
reported for other genes [38, 39].
MiR-152-3p promoter methylation has also been reported
in endometrial cancer [40] and in MLL-rearranged infant
acute lymphoblastic leukemia [41]. In accordance with previ-
ous reports, our results also suggest an onco-suppressor
function for miR-152-3p in PCa. Indeed, in non-small cell
lung cancer miR-152-3p suppressed cell proliferation, colony
formation, migration and invasion [42], in endometrial can-
cer miR-152-3p restored expression prevented tumor cell
growth both in vitro and in vivo [40], and in ovarian cancer
miR-152-3p was suggested to contribute to cisplatin resist-
ance in vitro and in vivo through direct DNMT1 targeting
[43]. Moreover, in the TCGA PCa cohort, DNMT1 upregula-
tion associated with miR-152 promoter hypermethylation
(Pearson’s = 0.12, p = 0.0236), although with limited statistical
significance [26]. Interestingly, in prostatectomy samples,
lower miR-152-3p expression levels were previously signifi-
cantly associated with higher risk for biochemical recurrence,
although only in univariable analysis [44]. Concordantly, our
study shows miR-152-3p has prognostic value, although only
in the TCGA cohort. Daniunaite et al. showed, using
Kaplan-Meier analysis, that mir-152 promoter hypermethyla-
tion had a significant negative impact on BCR-free survival
[26]. However, in a recent study aiming at PCa early detec-
tion, miR-152-3p expression did not discriminate PCa pa-
tients from the matched healthy controls in plasma samples
[45]. Moreover, TMEM97 and NOL4 expression levels did
not associate with patients’ prognosis in both cohorts.
In vitro functional assays demonstrated that miR-152-
3p controls cell viability in PCa cells acting as S and G2/
Fig. 6 miR-152-3p is valuable prognostic biomarker in PCa. a–c Disease-free survival analyses were performed in PCa patients from the TCGA
dataset. a High miR-152-3p expression levels significantly associated with longer disease-free survival (p = 0.004; Log-rank test). b TMEM97 and c
NOL4 expression do not present prognostic value
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M cell-cycle transitions regulator, in both cell lines tested,
but more expressively PC3 cells. However, these effects
might be cell-context dependent. In line with functional
assays’ results, miR-152-3p overexpression associated with
different specific transcript alterations depending on the
tested cell line. Our results indicate that miR-152-3p fine-
tunes the expression of several genes involved in the
MAPK/ERK, TFG-Beta, JAK–STAT3 and EMT pathways.
Thus, our data not only supports that miR-152-3p is a
promising molecular target that inhibits PCa cell cycle
and invasion [25, 46], but also demonstrates its role in
apoptosis regulation. Since these biological processes are
critical for cancer progression, a major role for miR-152-
3p in PCa progression might be anticipated.
To better understand the role of miR-152-3p, we
attempted to identify putative targets. In silico analysis
followed by validation in two independent patient cohorts
indicated NOL4 (nucleolar protein 4) and TMEM97
(transmembrane protein 97) as miR-152-3p targets. Al-
though no information is available for the role of NOL4 in
cancer, TMEM97 has been shown to be upregulated in
several malignancies, including glioma [47] as well as
colorectal [48] and ovarian [49] cancers. Interestingly, in
glioma cells, TMEM97 depletion inhibited cancer cell
growth and metastasis formation, in parallel with deregu-
lation of EMT-related genes. In our model, TMEM97 dis-
ruption decreased LNCaP proliferation, further suggesting
its involvement in cell growth. Remarkably, increased
TMEM97 expression correlated with shorter survival in
glioma [47], ovarian [49], non-small cell lung [50], and
colorectal [48] cancer patients. Moreover, TMEM97 cyto-
plasmic expression has been positively correlated with
PCNA expression [48], which acts as a scaffold to recruit
proteins involved in DNA replication or DNA repair, be-
ing required for post-replication repair [51]. Remarkably,
in our study, miR-152-3p overexpression associated with
PCNA downregulation in both cell lines. Therefore, since
TMEM97 might be functionally associated with PCNA
[52], it might suggest that both are controlled by miR-
152-3p. Concerning other previously reported miR-152-
3p’s targets, we were not able to confirm DNMT1 as a
miR-152-3p’s direct target [25, 43, 53].
Conclusions
In conclusion, this study uncovered novel miRNAs
downregulated by aberrant DNA methylation, including
a transcriptional unit formed by COPZ2-miR-152-3p.
Furthermore, it was demonstrated that miR-152-3p
downregulation is a common feature in PCa, favoring
the acquisition and development of the malignant traits,
as in vitro miR-152-3p’s restored expression attenuated
PCa cell phenotype, by impairment of cell viability, cell
cycle progression and invasion, through targeting of sev-
eral genes involved in critical cancer-related pathways.
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Additional file 1: Supplementary information. Table S1 Primers and
TaqMan assays used in this study; Table S2 microRNAs selected for
evaluation in TCGA dataset; Table S3 Putative miR-152 target genes
determined by multiple in silico prediction tools; Figure S1 Flow chart
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microRNAs at the TCGA cohort from the initial microRNA profiling by
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at the TCGA cohort derived from the DNA methylation mapping by
450 K Illumina’s array; Figure S4 Efficiency of miR-152 mimic’s transfection
in PCa cell lines; Figure S5 TIDE analysis of deletions/insertions caused by
each sgRNA targeting TMEM97. (PDF 4188 kb)
Table 2 Disease-free survival analysis by Cox regression in TCGA
patients
DFS Multivariable analysis
HR 95% CI for HR p value
mir152
mir152 expression levela 0.228 0.072–0.722 0.012
Age 0.999 0.970–1.028 0.928
Gleason Scoreb
6 < 0.0001
7 5.528 0.754–40.536 0.093
8 11.104 1.455–84.709 0.020
9 23.559 3.247–170.946 0.002
10 24.146 1.502–388.242 0.025
TMEM97
TMEM97 expression levela 1.007 0.550–1844 0.980
Age 1.000 0.971–1.029 0.978
Gleason Scoreb
6 < 0.0001
7 5.369 0.732–39.373 0.098
8 10.978 1.438–83.790 0.002
9 23.087 3.179–167.641 0.005
10 30.812 2.786–340.785 0.978
NOL4
NOL4 expression levela 0.778 0.392–1.545 0.473
Age 1.000 0.972–1.029 0.979
Gleason Scoreb
6 < 0.0001
7 5.309 0.724–38.935 0.101
8 10.967 1.438–83.629 0.021
9 22.911 3.158–166.213 0.002
10 31.102 2.811–344.117 0.005
p value significant when p < 0.05
HR hazard ratio, CI confidence interval.
aReference group: high expression level
bReference group: Gleason Score 6
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